Press Releases

MDx-Chex® for BC-GP and BC-GN, new full-process, molecular diagnostics quality controls for bloodstream infections, receive FDA clearance La Vista, Nebraska – Streck is pleased to announce that MDx-Chex® for BC-GP […]

Streck Announces Series B Investment in Ceres Nanosciences La Vista, Nebraska – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be […]

Streck introduces viral extraction kit for clinical samples La Vista, NE – Streck is pleased to announce the commercialization of Streck® Viral Extraction Kit with partner Ceres Nanosciences. Streck has […]

Streck’s first-of-its-kind molecular diagnostics quality control MDx-Chex for BCID2 receives FDA clearance La Vista, NE –Streck is pleased to announce MDx-Chex™ for BCID2, a first-of-its-kind quality control designed to meet […]

Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution La Vista, NE –Streck is pleased to announce the partnership with Ceres Nanosciences to distribute Nanotrap® Magnetic Virus […]

Streck is pleased to announce MDx-Chex™ for BCID2, a first-of-its-kind quality control designed to meet the standards for verifying the performance of sample-to-result molecular tests for sepsis. MDx-Chex for BCID2 is For Research Use Only. Not for use in diagnostic procedures.

Streck Cell-Free DNA BCT received U.S. Food and Drug Administration De Novo clearance for In Vitro Diagnostic use when paired with the Guardant360 CDx liquid biopsy assay. Cell-Free DNA BCT is the first and only circulating nucleic acid blood collection tube to be cleared for use with liquid biopsy.

Biodesix, Inc. and Streck, Inc. today announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.